Difference between revisions of "Eculizumab (Soliris)"
(updated content) |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH)and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).<ref name="insert">[http://www.soliris.net/indications/soliris_pi.pdf Eculizumab (Soliris) package insert]</ref><ref>[[Media:Eculizumab.pdf | Eculizumab (Soliris) package insert (locally hosted backup)]]</ref><ref>[http://soliris.net Soliris manufacturer's website]</ref> | + | Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).<ref name="insert">[http://www.soliris.net/indications/soliris_pi.pdf Eculizumab (Soliris) package insert]</ref><ref>[[Media:Eculizumab.pdf | Eculizumab (Soliris) package insert (locally hosted backup)]]</ref><ref>[http://soliris.net Soliris manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 07:28, 28 February 2013
General information
Class/mechanism: Complement inhibitor; monoclonal antibody that binds to complement protein C5, preventing its cleavage to C5a and C5b and the formation of the terminal complement complex C5b-9. Eculizumab is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic-uremic syndrome (aHUS)
Patient drug information
- Eculizumab (Soliris) package insert pages 7-8[1]
- Brief patient counseling information can be found on page 6 of the package insert[1]
- Eculizumab (Soliris) patient drug information (Chemocare)[5]
- Eculizumab (Soliris) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 1.3 Eculizumab (Soliris) package insert
- ↑ Eculizumab (Soliris) package insert (locally hosted backup)
- ↑ Soliris manufacturer's website
- ↑ Soliris Risk Evaluation and Mitigation Strategy (REMS) Site
- ↑ Eculizumab (Soliris) patient drug information (Chemocare)
- ↑ Eculizumab (Soliris) patient drug information (UpToDate)